Praxis Precision Medicines, Inc. 8-K

What Happened

• Praxis Precision Medicines, Inc. filed a Form 8-K on January 6, 2026 (Item 2.02) announcing a preliminary, unaudited estimate that the company held approximately $925 million in cash, cash equivalents and marketable securities as of December 31, 2025. Management notes this figure is based on preliminary estimates and subject to completion of year-end close and audit procedures.

Key Details

• Reported amount: approximately $925 million in cash, cash equivalents and marketable securities as of 12/31/2025.
• Status: preliminary, unaudited information based on management estimates; independent auditors have not audited or reviewed this estimate.
• Filing treatment: the information is being furnished (not “filed”) and is therefore not subject to Section 18 liability or automatic incorporation by reference in other filings.
• Forward-looking caution: company warns the figure may change after financial close and audit and points to risk disclosures in its prior SEC filings.

Why It Matters

• Liquidity snapshot: the reported cash and marketable securities figure gives investors a high-level view of Praxis’s year-end liquidity and ability to fund operations and clinical programs without implying finalized results.
• Caveats for investors: because the amount is preliminary and unaudited, investors should wait for the company’s audited financial statements and full Form 10-K for final, comprehensive financial results before making decisions.